Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Steven P. Treon(Dana-Farber Cancer Institute), Jorge J. Castillo(Dana-Farber Cancer Institute), Christopher J. Patterson(Dana-Farber Cancer Institute), Andrew R. Branagan(Massachusetts General Hospital), Jacob P. Laubach(Harvard University), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Ranjana H. Advani(Stanford Medicine), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Lian Xu(Huazhong Agricultural University), Irene M. Ghobrial(Dana-Farber Cancer Institute), Xia Liu(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University)
Cited by 150
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k